VERI-MET
Metabolic Remodelling in Worsening Heart Failure Treated With Vericiguat: A Prospective Multi-Omics Study Integrating Cardiac Imaging and Endothelial Function
Sponsor study identifier
observational
30
1 country
1
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
November 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention. Vericiguat is a medication used in certain patients with heart failure whose symptoms have recently worsened. The aim of this study is to better understand how vericiguat treatment is associated with changes in metabolism, heart function, and blood vessel health in patients with heart failure. This is a prospective, observational study conducted at a single hospital in Italy. Researchers will collect clinical information and analyze biological samples to investigate changes in molecules involved in energy production, inflammation, and cardiovascular function. Heart imaging and assessments of blood vessel function will also be used to better understand the patients' cardiovascular health. The study will explore whether these biological and cardiovascular measurements are associated with treatment with vericiguat and whether they could help identify patients who may benefit most from this therapy. The results may improve our understanding of heart failure and support more personalized treatment strategies in the future.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 21, 2026
Actual (reported)October 28, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Changes in Plasma Metabolomic and Lipidomic Profiles Following Vericiguat Initiation
Changes in the relative abundance of circulating metabolites and lipid species from baseline to 3 and 6 months after vericiguat initiation, assessed using untargeted liquid chromatography-mass spectrometry. Longitudinal changes will be analyzed to identify significantly altered molecular features and metabolic pathways associated with treatment exposure.
Baseline, 3 months, and 6 months
Change in Left Ventricular Global Longitudinal Strain
Baseline, 3 months, and 6 months
Change in Left Ventricular Global Longitudinal Strain
Baseline, 3 months, and 6 months
Vericiguat-Treated Patients
The study population consists of adult patients with worsening heart failure and left ventricular ejection fraction below 45%, hospitalized for heart failure decompensation or evaluated in an outpatient setting. Eligible patients are receiving guideline-directed medical therapy and are initiating vericiguat as part of routine clinical management. Participants will be prospectively enrolled at the Cardiology Unit of the AOR San Carlo Hospital in Potenza, Italy, and undergo clinical, biochemical, echocardiographic, and metabolomic assessments at baseline, 3 months, and 6 months.
Azienda Ospedaliera Regionale San Carlo di Potenza
Potenza, Basilicate, 85100, Italy
Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, Freitas C, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022 Nov;24(11):2029-2036. doi: 10.1002/ejhf.2720. Epub 2022 Nov 16.
Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O'Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA Cardiol. 2021 Jun 1;6(6):706-712. doi: 10.1001/jamacardio.2020.6455.
blood plasma
First Submitted
October 21, 2026
First Posted
October 28, 2026
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
November 1, 2027
COgnitioN With VERiciGuat Evaluation in Heart Failure
Contact the study team to confirm eligibility.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O'Connor CM; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 29, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: